Literature DB >> 11696280

Hepatopulmonary Syndrome and Portopulmonary Hypertension.

Michael J. Krowka1.   

Abstract

In patients with hepatopulmonary syndrome, supplemental oxygen and liver transplantation are the usual treatments of choice. Pharmacologic approaches have limited success in improving hypoxemia. Interventional radiology procedures may improve arterial hypoxemia in highly selected patients. In patients with portopulmonary hypertension, continuous infusion with intravenous epoprostenol (prostaglandin I(2)) can significantly improve pulmonary hemodynamics. Outcome following liver transplantation is variable; increased cardiopulmonary mortality occurs in patients with moderate to severe pulmonary hypertension.

Entities:  

Year:  2001        PMID: 11696280     DOI: 10.1007/s11938-001-0019-1

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  39 in total

1.  Inhaled nitric oxide reduces pulmonary artery pressures in portopulmonary hypertension.

Authors:  J Y Findlay; B A Harrison; D J Plevak; M J Krowka
Journal:  Liver Transpl Surg       Date:  1999-09

2.  Isosorbide-5-mononitrate in the treatment of pulmonary hypertension associated with portal hypertension.

Authors:  J Ribas; J Angrill; J A Barberà; J C García-Pagán; J Roca; J Bosch; R Rodriguez-Roisin
Journal:  Eur Respir J       Date:  1999-01       Impact factor: 16.671

3.  Haemodynamic adaptation two months after transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients.

Authors:  L A Colombato; L Spahr; J P Martinet; M P Dufresne; M Lafortune; D Fenyves; G Pomier-Layrargues
Journal:  Gut       Date:  1996-10       Impact factor: 23.059

4.  Hepatopulmonary syndrome versus portopulmonary hypertension: distinctions and dilemmas.

Authors:  M J Krowka
Journal:  Hepatology       Date:  1997-05       Impact factor: 17.425

5.  Long-term outcome of living related liver transplantation for patients with intrapulmonary shunting and strategy for complications.

Authors:  H Egawa; M Kasahara; Y Inomata; S Uemoto; K Asonuma; S Fujita; T Kiuchi; M Hayashi; T Yonemura; M Yoshibayashi; Y Adachi; J A Shapiro; K Tanaka
Journal:  Transplantation       Date:  1999-03-15       Impact factor: 4.939

6.  Reversibility of pulmonary hypertension after liver transplantation: a case report.

Authors:  V Scott; A De Wolf; Y Kang; M Martin; R Selby; J Fung; H Doyle; G Ziady; I Paradis; A Miro
Journal:  Transplant Proc       Date:  1993-04       Impact factor: 1.066

7.  Pulmonary hypertension and liver transplantation.

Authors:  A M De Wolf; V L Scott; T Gasior; Y Kang
Journal:  Anesthesiology       Date:  1993-01       Impact factor: 7.892

8.  Methylene blue improves the hepatopulmonary syndrome.

Authors:  P Schenk; C Madl; S Rezaie-Majd; S Lehr; C Müller
Journal:  Ann Intern Med       Date:  2000-11-07       Impact factor: 25.391

9.  Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension.

Authors:  M J Krowka; R P Frantz; M D McGoon; C Severson; D J Plevak; R H Wiesner
Journal:  Hepatology       Date:  1999-09       Impact factor: 17.425

10.  Use of transjugular intrahepatic portosystemic shunt as a bridge to liver transplantation in a patient with severe hepatopulmonary syndrome.

Authors:  H M Lasch; M W Fried; S L Zacks; P Odell; M W Johnson; D A Gerber; F S Sandhu; J H Fair; R Shrestha
Journal:  Liver Transpl       Date:  2001-02       Impact factor: 5.799

View more
  1 in total

1.  Liver Transplantation for Cholestatic Liver Disease.

Authors:  James Neuberger
Journal:  Curr Treat Options Gastroenterol       Date:  2003-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.